ABSTRACT
The literature regarding coronavirus disease of 2019 (COVID-19) infection in pediatrics indicates that children have less severe clinical presentations and lower mortality rates. There remains limited data regarding hematologic sequelae in pediatric patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Romiplostim has shown a platelet response in pediatric patients with chronic immune thrombocytopenic purpura, and eltrombopag is proven to increase platelet counts in patients with inherited thrombocytopenia. We review SARS-CoV-2-associated thrombocytopenia and present a pediatric patient with acute on chronic thrombocytopenia in the setting of COVID-19 with subsequent platelet recovery using romiplostim.
Subject(s)
COVID-19/complications , Receptors, Fc/therapeutic use , Recombinant Fusion Proteins/therapeutic use , SARS-CoV-2/isolation & purification , Thrombocytopenia/drug therapy , Thrombopoietin/therapeutic use , COVID-19/transmission , COVID-19/virology , Child , Humans , Male , Thrombocytopenia/pathology , Thrombocytopenia/virologySubject(s)
Rhabdoid Tumor/diagnosis , Soft Tissue Neoplasms/diagnosis , Fatal Outcome , Humans , Infant , Male , ShoulderABSTRACT
BACKGROUND: ALPS is a disorder of apoptosis resulting in accumulation of autoreactive lymphocytes, leading to marked lymphadenopathy, hepatosplenomegaly, and multilineage cytopenias due to splenic sequestration and/or autoimmune destruction often presenting in childhood. We summarize our experience of rituximab use during the last 8 years in 12 patients, 9 children, and 3 adults, out of 259 individuals with ALPS, belonging to 166 families currently enrolled in studies at the National Institutes of Health. METHODS: Refractory immune thrombocytopenia (platelet count <20,000) in nine patients and autoimmune hemolytic anemia (AIHA) in three patients led to treatment with rituximab. Among them, seven patients had undergone prior surgical splenectomy; three had significant splenomegaly; and two had no palpable spleen. RESULTS: In seven out of nine patients with ALPS and thrombocytopenia, rituximab therapy led to median response duration of 21 months (range 14-36 months). In contrast, none of the three children treated with rituximab for AIHA responded. Noted toxicities included profound and prolonged hypogammaglobulinemia in three patients requiring replacement IVIG, total absence of antibody response to polysaccharide vaccines lasting up to 4 years after rituximab infusions in one patient and prolonged neutropenia in one patient. CONCLUSION: Toxicities including hypogammaglobulinemia and neutropenia constitute an additional infection risk burden, especially in asplenic individuals, and may warrant avoidance of rituximab until other immunosuppressive medication options are exhausted. Long-term follow-up of ALPS patients with cytopenias after any treatment is necessary to determine relative risks and benefits.
Subject(s)
Anemia, Hemolytic, Autoimmune/drug therapy , Antibodies, Monoclonal/therapeutic use , Autoimmune Diseases/drug therapy , Immunosuppressive Agents/therapeutic use , Lymphoproliferative Disorders/drug therapy , Thrombocytopenia/drug therapy , Adolescent , Adult , Anemia, Hemolytic, Autoimmune/immunology , Antibodies, Monoclonal, Murine-Derived , Autoimmune Diseases/immunology , Child , Child, Preschool , Drug Resistance, Neoplasm , Humans , Infant , Lymphoproliferative Disorders/immunology , Middle Aged , Rituximab , Young AdultABSTRACT
A 2-week-old infant developed respiratory failure due to a mediastinal Kaposiform hemangioendothelioma that was complicated by thrombocytopenia and consumptive coagulopathy. Initial surgery was unsuccessful at removing the tumorous infiltration of mediastinal structures. Multiple transfusions with fresh frozen plasma, platelets, and red blood cells were needed for the consumptive coagulopathy, and ventilatory support was required for 5 months. Therapy for the tumor included methylprednisolone, aminocaproic acid, and vincristine, but a sustained response was achieved only after the initiation of alpha interferon. The patient was monitored closely and did not develop neurologic toxicity. This case demonstrates that interferon can be used to treat infants with Kaposiform hemangioendothelioma in life-threatening situations that do not respond to other forms of treatment.
Subject(s)
Anemia, Hemolytic/etiology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Disseminated Intravascular Coagulation/etiology , Hemangioendothelioma/complications , Interferon-alpha/therapeutic use , Mediastinal Neoplasms/complications , Respiratory Insufficiency/etiology , Thrombocytopenia/etiology , Aminocaproates/administration & dosage , Anemia, Hemolytic/therapy , Blood Component Transfusion , Combined Modality Therapy , Disseminated Intravascular Coagulation/therapy , Female , Hemangioendothelioma/drug therapy , Hemangioendothelioma/surgery , Humans , Infant, Newborn , Mediastinal Neoplasms/drug therapy , Mediastinal Neoplasms/surgery , Methylprednisolone/administration & dosage , Plasma , Respiration, Artificial , Respiratory Insufficiency/therapy , Syndrome , Thoracotomy , Thrombocytopenia/therapy , Thymectomy , Vincristine/administration & dosageABSTRACT
BACKGROUND: Hoyeraal-Hreidarsson syndrome is a dyskeratosis congenita-related telomere biology disorder that presents in infancy with intrauterine growth retardation, immunodeficiency, and cerebellar hypoplasia in addition to the triad of nail dysplasia, skin pigmentation, and oral leukoplakia. Individuals with Hoyeraal-Hreidarsson syndrome often develop bone marrow failure in early childhood. Germline mutations in DKC1, TERT, TINF2, RTEL1, ACD, or PARN cause about 60% of individuals with Hoyeraal-Hreidarsson syndrome. PATIENT DESCRIPTION: We describe 14 years of follow-up of an individual with Hoyeraal-Hreidarsson syndrome who initially presented as an infant with intrauterine growth retardation, microcephaly, and central nervous system calcifications. He was diagnosed with Hoyeraal-Hreidarsson syndrome at age 6 years and had a complicated medical history including severe developmental delay, cerebellar hypoplasia, esophageal and urethral stenosis, hip avascular necrosis, immunodeficiency, and bone marrow failure evolving to myelodysplastic syndrome requiring hematopoietic cell transplantation at age 14 years. He had progressive skin pigmentation, oral leukoplakia, and nail dysplasia leading to anonychia. Whole exome sequencing identified novel biallelic variants in PARN. CONCLUSIONS: This patient illustrates that the constellation of intrauterine growth retardation, central nervous system calcifications, and cerebellar hypoplasia, esophageal or urethral stenosis, and cytopenias, in the absence of congenital infection, may be due to Hoyeraal-Hreidarsson syndrome. Early diagnosis of Hoyeraal-Hreidarsson syndrome is important to optimize medical management and provide genetic counseling.
Subject(s)
Dyskeratosis Congenita/genetics , Exoribonucleases/genetics , Fetal Growth Retardation/genetics , Intellectual Disability/genetics , Microcephaly/genetics , Mutation/genetics , DNA Mutational Analysis , Dyskeratosis Congenita/diagnostic imaging , Dyskeratosis Congenita/pathology , Dyskeratosis Congenita/therapy , Exome , Fetal Growth Retardation/diagnostic imaging , Fetal Growth Retardation/pathology , Fetal Growth Retardation/therapy , Humans , Intellectual Disability/diagnostic imaging , Intellectual Disability/pathology , Intellectual Disability/therapy , Longitudinal Studies , Male , Microcephaly/diagnostic imaging , Microcephaly/pathology , Microcephaly/therapy , Young AdultABSTRACT
PURPOSE: We undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers to determine the feasibility of genome-guided precision therapy. EXPERIMENTAL DESIGN: Patients with non-central nervous system solid tumors underwent a combination of whole exome sequencing (WES), whole transcriptome sequencing (WTS), and high-density single-nucleotide polymorphism array analysis of the tumor, with WES of matched germline DNA. Clinically actionable alterations were identified as a reportable germline mutation, a diagnosis change, or a somatic event (including a single nucleotide variant, an indel, an amplification, a deletion, or a fusion gene), which could be targeted with drugs in existing clinical trials or with FDA-approved drugs. RESULTS: Fifty-nine patients in 20 diagnostic categories were enrolled from 2010 to 2014. Ages ranged from 7 months to 25 years old. Seventy-three percent of the patients had prior chemotherapy, and the tumors from these patients with relapsed or refractory cancers had a higher mutational burden than that reported in the literature. Thirty patients (51% of total) had clinically actionable mutations, of which 24 (41%) had a mutation that was currently targetable in a clinical trial setting, 4 patients (7%) had a change in diagnosis, and 7 patients (12%) had a reportable germline mutation. CONCLUSIONS: We found a remarkably high number of clinically actionable mutations in 51% of the patients, and 12% with significant germline mutations. We demonstrated the clinical feasibility of next-generation sequencing in a diverse population of relapsed and refractory pediatric solid tumors. Clin Cancer Res; 22(15); 3810-20. ©2016 AACR.
Subject(s)
Genomics , Neoplasms/genetics , Neoplasms/therapy , Precision Medicine , Adolescent , Adult , Biomarkers, Tumor , Child , Child, Preschool , Drug Resistance, Neoplasm , Female , Genomics/methods , Germ-Line Mutation , Humans , Infant , Male , Molecular Targeted Therapy , Mutation , Neoplasms/diagnosis , Polymorphism, Single Nucleotide , Precision Medicine/methods , Recurrence , Exome Sequencing , Young AdultABSTRACT
Nocardia species are ubiquitous soil-borne organisms that most commonly cause invasive disease in patients with defective cell-mediated immunity. We report a case of recurrent Nocardia sepsis in a patient with sickle cell disease and chronic iron overload, who was undergoing high-dose infusions of deferoxamine through a central venous catheter.
ABSTRACT
Iron deficiency is usually attributed to chronic blood loss or inadequate dietary intake. Here, we show that iron deficiency anemia refractory to oral iron therapy can be caused by germline mutations in TMPRSS6, which encodes a type II transmembrane serine protease produced by the liver that regulates the expression of the systemic iron regulatory hormone hepcidin. These findings demonstrate that TMPRSS6 is essential for normal systemic iron homeostasis in humans.